Aobo Li

Aobo Li

Auto-generated profile, based on publicly available information

Aobo Li

Inspira Medical Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2018 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
WGWei Gong
Wei Gong
YMYoucai Ma
Youcai Ma
ALAobo Li
Aobo Li
HSHan Shi
Han Shi
SNShaoping Nie
Shaoping Nie
Summary: Background/Aims: Cardiac rupture (CR) is a catastrophic complication of acute myocardial infarction (MI). At present, there are no effective pharmacological strategies for preventing post‐MI rupture. Here we investigated the effect of trimetazidine (TMZ) on post‐MI CR.Methods: MI models were induced by left coronary artery ligation in male C57BL/6 mice. Animals allocated to the rupture incidence were closely monitored for 7 days; autopsy was performed once animals were found dead to determine the reason of death. Heart function was detected by echocardiography. Oxidative stress markers and matrix metalloproteinases (MMPs) were analyzed by Western Blotting.Results: TMZ markedly reduced the post‐MI CR incidence of mice. We found that the expression of metalloproteinase (MMP) ‐2 and MMP‐9 in the TMZ‐treated group was significantly lower than the saline‐treated group. Further, TMZ markedly attenuated MI‐induced oxidative stress. To investigate the mechanism of the effect of TMZ on CR, we pretreated H9c2 cells with H2O2 and found that TMZ treatment markedly decreased H2O2‐induced MMP‐2 and MMP‐9 expression. TMZ prevents CR through inhibition of oxidative stress, which is attributable to the down‐regulation of MMP‐2, MMP‐9 expression.Conclusions: Our findings indicate that TMZ suppresses oxidative stress, inhibits MMP‐2 and MMP‐9 expression, and prevents CR in mice with MI.

25 May 2024 in Obesity Pillars
Verified
Journal Article
Open access
RDRupak Desai
Rupak Desai
ALAobo Li
Aobo Li
AMAvilash Mondal
Avilash Mondal
SSSashwath Srikanth
Sashwath Srikanth
AFAlka Farmer
Alka Farmer
LZLin Zheng
Lin Zheng
The obesity paradox in patients with coronary artery disease is well established, but the role of the metabolic syndrome associated with obesity is not well studied. Our study aims to evaluate the in-hospital outcomes of percutaneous coronary intervention (PCI) in metabolically healthy individuals with obesity (MHO) and metabolically unhealthy (MUHO) individuals with obesity over 65 years of age with acute coronary syndrome (ACS) between 2016 and 2020. This was a retrospective and observational study. Patients were identified through utilizing the National Inpatient Sample (NIS) Database (2016–2020) and ICD-10 codes. By employing a t-test and Pearson's Chi-square test, we assessed and contrasted the initial attributes, concurrent conditions, and results pertaining to all-cause mortality (ACM), cardiogenic shock (CS), length of stay (LOS), and hospitalization expense. Moreover, propensity score matching was conducted in a 1:1 ratio with respect to age, gender, and race. We also utilized multivariable logistic regression to compare MHO and MUHO in terms of the impact on all-cause mortality. Out of a total of 135,395 patients identified, 2995 patients with MUHO were matched with 2995 MHO patients. Patients in the MUHO group had a higher prevalence of chronic pulmonary disease (24.9 % vs. 19.5 %), peripheral vascular disease (9.3 % vs. 6.7 %), hypothyroidism (16 % vs. 11.5 %), prior myocardial infarction (15.9 % vs. 6.2 %), and prior stroke (7.5 % vs. 2.8 %). Patients in the MHO group had a higher ACM (12.4 % vs. 2.8 %, p < 0.001), CS (18.55 % vs. 7 %, p < 0.001), stroke (2.2 % vs. 1 %, p < 0.001), ventricular assist device insertions (5.2 % vs. 2.7 %, p < 0.001), and IABP insertions (8.8 % vs. 3.8 %) compared to the MUHO cohort. Our study revealed an obesity paradox in individuals over 65 years of age undergoing PCI demonstrating worse outcomes, including higher in-hospital mortality, CS, stroke, Ventricular assist device and IABP insertion in MHO patients compared to the MUHO cohort.

17 February 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
ATAmro Taha
Amro Taha
AMAvilash Mondal
Avilash Mondal
UAUsman Ali Akbar
Usman Ali Akbar
ALAobo Li
Aobo Li
HSHarigopal Sandhyavenu
Harigopal Sandhyavenu
SBSudarshan Balla
Sudarshan Balla
Background: Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists. Methods: Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM. Results: Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P <0.001), major bleeding (HR, 0.85 [95% CI, 0.73–0.99]; P =0.03), and intracranial hemorrhage (HR, 0.54 [95% CI, 0.36–0.79]; P =0.001) compared with vitamin K antagonists. No differences were observed in the rates of ischemic stroke (HR, 0.94 [95% CI, 0.73–1.2]; P =0.6) or the composite of stroke or systemic thromboembolism (HR, 0.87 [95% CI, 0.69–1.10]; P =0.25), gastrointestinal bleeding (HR, 0.97 [95% CI, 0.77–1.22]; P =0.82), or all‐cause hospitalizations (HR, 1.07 [95% CI, 0.93–1.07]; P =0.051). In the subgroup with obstructive HCM, DOAC use was associated with a reduced risk of all‐cause mortality (HR, 0.80 [95% CI, 0.66–0.99]; P =0.035) and major bleeding (HR, 0.76 [95% CI, 0.61–0.96]; P =0.02) without stroke or thromboembolic risk reduction (HR, 0.69 [95% CI, 0.47–1.01]; P =0.05). Conclusions: Among patients with HCM‐atrial fibrillation, DOACs were associated with lower mortality and bleeding risk compared with vitamin K antagonists, with no increased risk of stroke or systemic thromboembolism.